GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fate Therapeutics Inc (FRA:F6T) » Definitions » Equity-to-Asset

Fate Therapeutics (FRA:F6T) Equity-to-Asset

: 0.73 (As of Dec. 2023)
View and export this data going back to 2013. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Fate Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €337.84 Mil. Fate Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was €464.20 Mil. Therefore, Fate Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.73.

The historical rank and industry rank for Fate Therapeutics's Equity-to-Asset or its related term are showing as below:

FRA:F6T' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.55   Med: 0.73   Max: 0.81
Current: 0.73

During the past 13 years, the highest Equity to Asset Ratio of Fate Therapeutics was 0.81. The lowest was 0.55. And the median was 0.73.

FRA:F6T's Equity-to-Asset is ranked better than
57.47% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs FRA:F6T: 0.73

Fate Therapeutics Equity-to-Asset Historical Data

The historical data trend for Fate Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fate Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.81 0.62 0.74 0.69 0.73

Fate Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.76 0.75 0.74 0.73

Competitive Comparison

For the Biotechnology subindustry, Fate Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fate Therapeutics Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Fate Therapeutics's Equity-to-Asset falls into.



Fate Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Fate Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=337.838/464.201
=0.73

Fate Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=337.838/464.201
=0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fate Therapeutics  (FRA:F6T) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Fate Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Fate Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Fate Therapeutics (FRA:F6T) Business Description

Traded in Other Exchanges
Address
12278 Scripps Summit Drive, San Diego, CA, USA, 92131
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Fate Therapeutics (FRA:F6T) Headlines

No Headlines